SCOPUS 정보 검색 플랫폼

Volumn 48, Issue 11, 2009, Pages 1308-1317

Systemic therapy of metastatic renal cell carcinoma. From many options to the therapeutic strategy;Systemtherapie des metastasierten Nierenzellkarzinoms. Von der Vielzahl der Möglichkeiten zur therapeutischen Strategie

(4) Ringhoffer, M a,b Rinnab, L a Kufer R a Greiner, J a

a UNIVERSITY HOSPITAL ULM (Germany)

b STÄDTISCHES KLINIKUM KARLSRUHE (Germany)

Author keywords

Metastatic renal cell carcinoma; MTor inhibitors; Systemic therapy; Therapy recommendations; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DEXPANTHENOL; EVEROLIMUS; INTERLEUKIN 2; LOPERAMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOTANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANEMIA; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG EFFICACY; ECG ABNORMALITY; FATIGUE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; IMMUNOMODULATION; KIDNEY CARCINOMA; MONOTHERAPY; NEPHRECTOMY; PATIENT COMPLIANCE; PROTEINURIA; REVIEW; RISK ASSESSMENT; SCORING SYSTEM;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES;

EID: 71049121810 PISSN: 03402592 EISSN: None Source Type: Journal
DOI: 10.1007/s00120-009-2109-y Document Type: Review

Times cited : (1)

References (44)

1
- 16644373473
- Role of VHL gene mutation in human cancer
- DOI 10.1200/JCO.2004.05.061
- Kim 2004 J Clin Oncol 22 4991 10.1200/JCO.2004.05.061 15611513 1:CAS:528:DC%2BD2MXptVWrsw%3D%3D (Pubitemid 46646218)
- (2004) Journal of Clinical Oncology , vol.22 , Issue.24 , pp. 4991-5004
- Kim, W.Y.¹ Kaelin, W.G.²

2
- 28844484134
- Renal-cell carcinoma
- DOI 10.1056/NEJMra043172
- Cohen 2005 N Engl J Med 353 2477 10.1056/NEJMra043172 16339096 1:CAS:528:DC%2BD2MXhtlShurnM (Pubitemid 41770167)
- (2005) New England Journal of Medicine , vol.353 , Issue.23 , pp. 2477-2490
- Cohen, H.T.¹ McGovern, F.J.²

3
- 33845309430
- Activation of the mTOR Signaling Pathway in Renal Clear Cell Carcinoma
- DOI 10.1016/j.juro.2006.08.076, PII S0022534706021975
- Robb 2007 J Urol 177 346 10.1016/j.juro.2006.08.076 17162089 (Pubitemid 44879483)
- (2007) Journal of Urology , vol.177 , Issue.1 , pp. 346-352
- Robb, V.A.¹ Karbowniczek, M.² Klein-Szanto, A.J.³ Henske, E.P.⁴

4
- 48649098245
- 10.1016/j.juro.2008.05.015 18635227 1:CAS:528:DC%2BD1cXhtVKmsbvE
- Choueiri 2008 J Urol 180 860 10.1016/j.juro.2008.05.015 18635227 1:CAS:528:DC%2BD1cXhtVKmsbvE
- (2008) J Urol , vol.180 , pp. 860
- Choueiri¹

5
- 12944266844
- 15709180 1:CAS:528:DC%2BD2MXht1ynt7o%3D
- Lidgren 2005 Clin Cancer Res 11 1129 15709180 1:CAS:528: DC%2BD2MXht1ynt7o%3D
- (2005) Clin Cancer Res , vol.11 , pp. 1129
- Lidgren¹

6
- 55549106466
- 10.1200/JCO.2008.18.2170
- Patel 2008 J Clin Oncol 26 5008 10.1200/JCO.2008.18.2170
- (2008) J Clin Oncol , vol.26 , pp. 5008
- Patel¹

7
- 3342967945
- G250/MN by HIF-1α in clear cell renal cell carcinoma
- DOI 10.1038/sj.onc.1207764
- Grabmaier 2004 Oncogene 23 5624 10.1038/sj.onc.1207764 15184875 1:CAS:528:DC%2BD2cXlvVehsb0%3D (Pubitemid 39093040)
- (2004) Oncogene , vol.23 , Issue.33 , pp. 5624-5631
- Grabmaier, K.¹ De Weijert, M.C.A.² Verhaegh, G.W.³ Schalken, J.A.⁴ Oosterwijk, E.⁵

8
- 27144491977
- Frog skin yields antiviral peptides
- DOI 10.1038/nm1005-1046, PII N10051046
- Thomas 2005 Nat Med 11 992 10.1038/nm1005-1046 1:CAS:528: DC%2BD2MXhtVOiurnP (Pubitemid 41486819)
- (2005) Nature Medicine , vol.11 , Issue.10 , pp. 1046
- Thomas, C.¹

9
- 61449137045
- 10.1097/PPO.0b013e31819765da
- Figlin 2009 Cancer 15 7 10.1097/PPO.0b013e31819765da
- (2009) Cancer , vol.15 , pp. 7
- Figlin¹

10
- 0035934596
- Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial
- DOI 10.1016/S0140-6736(01)06103-7
- Mickisch 2001 Lancet 358 966 10.1016/S0140-6736(01)06103-7 11583750 1:CAS:528:DC%2BD3MXntF2qtbw%3D (Pubitemid 32913522)
- (2001) Lancet , vol.358 , Issue.9286 , pp. 966-970
- Mickisch, G.H.J.¹ Garin, A.² Van Poppel, H.³ De Prijck, L.⁴ Sylvester, R.⁵

11
- 0035818877
- Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
- DOI 10.1056/NEJMoa003013
- Flanigan 2001 N Engl J Med 345 1655 10.1056/NEJMoa003013 11759643 1:CAS:528:DC%2BD3MXovFKjt74%3D (Pubitemid 33126820)
- (2001) New England Journal of Medicine , vol.345 , Issue.23 , pp. 1655-1659
- Flanigan, R.C.¹ Salmon, S.E.² Blumenstein, B.A.³ Bearman, S.I.⁴ Roy, V.⁵ McGrath, P.C.⁶ Caton Jr., J.R.⁷ Munshi, N.⁸ Crawford, E.D.⁹

12
- 55349094251
- Szczylik 2008 J Clin Oncol 26 5124
- (2008) J Clin Oncol , vol.26 , pp. 5124
- Szczylik¹

13
- 0032772880
- 10561319 1:STN:280:DC%2BD3c%2FjtVSnug%3D%3D
- Motzer 1999 J Clin Oncol 17 2530 10561319 1:STN:280: DC%2BD3c%2FjtVSnug%3D%3D
- (1999) J Clin Oncol , vol.17 , pp. 2530
- Motzer¹

14
- 0036138580
- Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
- DOI 10.1200/JCO.20.1.289
- Motzer 2002 J Clin Oncol 20 289 10.1200/JCO.20.1.289 11773181 1:CAS:528:DC%2BD38XnsFeqtg%3D%3D (Pubitemid 34032623)
- (2002) Journal of Clinical Oncology , vol.20 , Issue.1 , pp. 289-296
- Motzer, R.J.¹ Bacik, J.² Murphy, B.A.³ Russo, P.⁴ Mazumdar, M.⁵

15
- 34249779568
- Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
- DOI 10.1056/NEJMoa066838
- Hudes 2007 N Engl J Med 356 2271 10.1056/NEJMoa066838 17538086 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
- (2007) New England Journal of Medicine , vol.356 , Issue.22 , pp. 2271-2281
- Hudes, G.¹ Carducci, M.² Tomczak, P.³ Dutcher, J.⁴ Figlin, R.⁵ Kapoor, A.⁶ Staroslawska, E.⁷ Sosman, J.⁸ McDermott, D.⁹ Bodrogi, I.¹⁰ Kovacevic, Z.¹¹ Lesovoy, V.¹² Schmidt-Wolf, I.G.H.¹³ Barbarash, O.¹⁴ Gokmen, E.¹⁵ O'Toole, T.¹⁶ Lustgarten, S.¹⁷ Moore, L.¹⁸ Motzer, R.J.¹⁹

16
- 33744954585
- Sunitinib in patients with metastatic renal cell carcinoma
- DOI 10.1001/jama.295.21.2516
- Motzer 2006 JAMA 295 2516 10.1001/jama.295.21.2516 16757724 1:CAS:528:DC%2BD28XlsV2rtLk%3D (Pubitemid 43854967)
- (2006) Journal of the American Medical Association , vol.295 , Issue.21 , pp. 2516-2524
- Motzer, R.J.¹ Rini, B.I.² Bukowski, R.M.³ Curti, B.D.⁴ George, D.J.⁵ Hudes, G.R.⁶ Redman, B.G.⁷ Margolin, K.A.⁸ Merchan, J.R.⁹ Wilding, G.¹⁰ Ginsberg, M.S.¹¹ Bacik, J.¹² Kim, S.T.¹³ Baum, C.M.¹⁴ Michaelson, M.D.¹⁵

17
- 33644833910
- Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
- DOI 10.1200/JCO.2005.02.2574
- Motzer 2006 J Clin Oncol 24 16 10.1200/JCO.2005.02.2574 16330672 1:CAS:528:DC%2BD28Xot1ChtA%3D%3D (Pubitemid 46630489)
- (2006) Journal of Clinical Oncology , vol.24 , Issue.1 , pp. 16-24
- Motzer, R.J.¹ Michaelson, M.D.² Redman, B.G.³ Hudes, G.R.⁴ Wilding, G.⁵ Figlin, R.A.⁶ Ginsberg, M.S.⁷ Kim, S.T.⁸ Baum, C.M.⁹ DePrimo, S.E.¹⁰ Li, J.Z.¹¹ Bello, C.L.¹² Theuer, C.P.¹³ George, D.J.¹⁴ Rini, B.I.¹⁵

18
- 33846181370
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
- DOI 10.1056/NEJMoa065044
- Motzer 2007 N Engl J Med 356 115 10.1056/NEJMoa065044 17215529 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
- (2007) New England Journal of Medicine , vol.356 , Issue.2 , pp. 115-124
- Motzer, R.J.¹ Hutson, T.E.² Tomczak, P.³ Michaelson, D.⁴ Bukowski, R.M.⁵ Rixe, O.⁶ Oudard, S.⁷ Negrier, S.⁸ Szczylik, C.⁹ Kim, S.T.¹⁰ Chen, I.¹¹ Bycott, P.W.¹² Baum, C.M.¹³ Figlin, R.A.¹⁴

19
- 68949145218
- Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
- Epub ahead on print
- Motzer RJ (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (Epub ahead on print)
- (2009) J Clin Oncol
- Motzer, R.J.¹

20
- 37849001813
- 10.1200/JCO.2007.13.3223 18165647 1:CAS:528:DC%2BD1cXhsVCrtr4%3D
- Choueiri 2008 J Clin Oncol 26 127 10.1200/JCO.2007.13.3223 18165647 1:CAS:528:DC%2BD1cXhsVCrtr4%3D
- (2008) J Clin Oncol , vol.26 , pp. 127
- Choueiri¹

21
- 65249166077
- 10.3816/CGC.2009.n.005 19213665 1:CAS:528:DC%2BD1MXjslKqs7k%3D
- Motzer 2009 Clin Genitourin Cancer 7 28 10.3816/CGC.2009.n.005 19213665 1:CAS:528:DC%2BD1MXjslKqs7k%3D
- (2009) Clin Genitourin Cancer , vol.7 , pp. 28
- Motzer¹

22
- 67649661872
- Hariharan S, Szczylik C, Porta C et al (2008) Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. 26(Suppl):5094
- (2008) Sunitinib in Metastatic Renal Cell Carcinoma (MRCC) Patients (Pts) with Brain Metastases (Mets): Data from An Expanded Access Trial , vol.26 , Issue.SUPPL. , pp. 5094
- Hariharan, S.¹ Szczylik, C.² Porta, C.³

23
- 33846148701
- Sorafenib in advanced clear-cell renal-cell carcinoma
- DOI 10.1056/NEJMoa060655
- Escudier 2007 N Engl J Med 356 125 10.1056/NEJMoa060655 17215530 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
- (2007) New England Journal of Medicine , vol.356 , Issue.2 , pp. 125-134
- Escudier, B.¹ Eisen, T.² Stadler, W.M.³ Szczylik, C.⁴ Oudard, S.⁵ Siebels, M.⁶ Negrier, S.⁷ Chevreau, C.⁸ Solska, E.⁹ Desai, A.A.¹⁰ Rolland, F.¹¹ Demkow, T.¹² Hutson, T.E.¹³ Gore, M.¹⁴ Freeman, S.¹⁵ Schwartz, B.¹⁶ Shan, M.¹⁷ Simantov, R.¹⁸ Bukowski, R.M.¹⁹

24
- 62449186539
- 10.1200/JCO.2008.19.3342 1:CAS:528:DC%2BD1MXktFKhsb8%3D
- Escudier 2008 J Clin Oncol 27 1280 10.1200/JCO.2008.19.3342 1:CAS:528:DC%2BD1MXktFKhsb8%3D
- (2008) J Clin Oncol , vol.27 , pp. 1280
- Escudier¹

25
- 54049134421
- 10.1093/jnci/djn319 18840822 1:CAS:528:DC%2BD1cXht1Oisb7J
- Eisen 2008 J Natl Cancer Inst 100 1454 10.1093/jnci/djn319 18840822 1:CAS:528:DC%2BD1cXht1Oisb7J
- (2008) J Natl Cancer Inst , vol.100 , pp. 1454
- Eisen¹

26
- 70349253166
- Sternberg 2009 J Clin Oncol 27 5021
- (2009) J Clin Oncol , vol.27 , pp. 5021
- Sternberg¹

27
- 1542398693
- Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
- DOI 10.1200/JCO.2004.08.185
- Atkins 2004 J Clin Oncol 22 909 10.1200/JCO.2004.08.185 14990647 1:CAS:528:DC%2BD2cXpsVKisr0%3D (Pubitemid 41103603)
- (2004) Journal of Clinical Oncology , vol.22 , Issue.5 , pp. 909-918
- Atkins, M.B.¹ Hidalgo, M.² Stadler, W.M.³ Logan, T.F.⁴ Dutcher, J.P.⁵ Hudes, G.R.⁶ Park, Y.⁷ Liou, S.-H.⁸ Marshall, B.⁹ Boni, J.P.¹⁰ Dukart, G.¹¹ Sherman, M.L.¹²

28
- 67651056360
- 10.1007/s12032-009-9177-0 19229667 1:CAS:528:DC%2BD1MXmtVKitr0%3D
- Dutcher 2009 Med Oncol 26 202 10.1007/s12032-009-9177-0 19229667 1:CAS:528:DC%2BD1MXmtVKitr0%3D
- (2009) Med Oncol , vol.26 , pp. 202
- Dutcher¹

29
- 48649107474
- 10.1016/S0140-6736(08)61039-9 18653228 1:CAS:528:DC%2BD1cXps1GmsLY%3D
- Motzer 2008 Lancet 372 449 10.1016/S0140-6736(08)61039-9 18653228 1:CAS:528:DC%2BD1cXps1GmsLY%3D
- (2008) Lancet , vol.372 , pp. 449
- Motzer¹

30
- 0042343801
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
- DOI 10.1056/NEJMoa021491
- Yang 2003 N Engl J Med 349 427 10.1056/NEJMoa021491 12890841 1:CAS:528:DC%2BD3sXms1Klu7w%3D (Pubitemid 36910021)
- (2003) New England Journal of Medicine , vol.349 , Issue.5 , pp. 427-434
- Yang, J.C.¹ Haworth, L.² Sherry, R.M.³ Hwu, P.⁴ Schwartzentruber, D.J.⁵ Topalian, S.L.⁶ Steinberg, S.M.⁷ Chen, H.X.⁸ Rosenberg, S.A.⁹

31
- 37349080670
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
- DOI 10.1016/S0140-6736(07)61904-7, PII S0140673607619047
- Escudier 2007 Lancet 370 2103 10.1016/S0140-6736(07)61904-7 18156031 (Pubitemid 350296300)
- (2007) Lancet , vol.370 , Issue.9605 , pp. 2103-2111
- Escudier, B.¹ Pluzanska, A.² Koralewski, P.³ Ravaud, A.⁴ Bracarda, S.⁵ Szczylik, C.⁶ Chevreau, C.⁷ Filipek, M.⁸ Melichar, B.⁹ Bajetta, E.¹⁰ Gorbunova, V.¹¹ Bay, J.-O.¹² Bodrogi, I.¹³ Jagiello-Gruszfeld, A.¹⁴ Moore, N.¹⁵

32
- 56749161699
- 10.1200/JCO.2008.16.9847 18936475 1:CAS:528:DC%2BD1MXhslClsA%3D%3D
- Rini 2008 J Clin Oncol 26 5422 10.1200/JCO.2008.16.9847 18936475 1:CAS:528:DC%2BD1MXhslClsA%3D%3D
- (2008) J Clin Oncol , vol.26 , pp. 5422
- Rini¹

33
- 48749092867
- 10.1093/annonc/mdn161 18408224 1:STN:280:DC%2BD1cvotVKmtQ%3D%3D
- Melichar 2008 Ann Oncol 19 1470 10.1093/annonc/mdn161 18408224 1:STN:280:DC%2BD1cvotVKmtQ%3D%3D
- (2008) Ann Oncol , vol.19 , pp. 1470
- Melichar¹

34
- 62849094732
- 10.1038/ni.1701 19295632 1:CAS:528:DC%2BD1MXjtlyms78%3D
- Ghoreschi 2009 Nat Immunol 10 356 10.1038/ni.1701 19295632 1:CAS:528:DC%2BD1MXjtlyms78%3D
- (2009) Nat Immunol , vol.10 , pp. 356
- Ghoreschi¹

35
- 55549097827
- 10.1200/JCO.2008.18.3137
- Sosman 2008 J Clin Oncol 26 5011 10.1200/JCO.2008.18.3137
- (2008) J Clin Oncol , vol.26 , pp. 5011
- Sosman¹

36
- 50849108567
- Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
- May 20 abstr 5010
- Whorf R, Hainsworth JD, Spigel DR et al (2008) Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 26:(May 20 suppl; abstr 5010)
- (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
- Whorf, R.¹ Hainsworth, J.D.² Spigel, D.R.³

37
- 70349379206
- Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients
- abstr 5039
- Merchan R, Pitot HC, Qin R et al (2009) Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients. J Clin Oncol 27(15 s, (suppl; abstr 5039))
- (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
- Merchan, R.¹ Pitot, H.C.² Qin, R.³

38
- 55949123335
- 10.1200/JCO.2007.15.6331 18838713
- Schmidinger 2008 J Clin Oncol 26 5204 10.1200/JCO.2007.15.6331 18838713
- (2008) J Clin Oncol , vol.26 , pp. 5204
- Schmidinger¹

39
- 36849023013
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
- DOI 10.1016/S0140-6736(07)61865-0, PII S0140673607618650
- Chu 2007 Lancet 370 2011 10.1016/S0140-6736(07)61865-0 18083403 1:CAS:528:DC%2BD2sXhsVent7bN (Pubitemid 350236338)
- (2007) Lancet , vol.370 , Issue.9604 , pp. 2011-2019
- Chu, T.F.¹ Rupnick, M.A.² Kerkela, R.³ Dallabrida, S.M.⁴ Zurakowski, D.⁵ Nguyen, L.⁶ Woulfe, K.⁷ Pravda, E.⁸ Cassiola, F.⁹ Desai, J.¹⁰ George, S.¹¹ Morgan, J.A.¹² Harris, D.M.¹³ Ismail, N.S.¹⁴ Chen, J.-H.¹⁵ Schoen, F.J.¹⁶ Van Den Abbeele, A.D.¹⁷ Demetri, G.D.¹⁸ Force, T.¹⁹ Chen, M.H.²⁰ more..

40
- 66149121478
- 10.1016/S1470-2045(09)70112-3 19482548 1:CAS:528:DC%2BD1MXms12jtbk%3D
- Hapani 2009 Lancet Oncol 10 559 10.1016/S1470-2045(09)70112-3 19482548 1:CAS:528:DC%2BD1MXms12jtbk%3D
- (2009) Lancet Oncol , vol.10 , pp. 559
- Hapani¹

41
- 41149108218
- 10.1016/j.eururo.2007.11.037 18054825 1:CAS:528:DC%2BD1cXns1ejsbc%3D
- Bhojani 2008 Eur Urol 53 917 10.1016/j.eururo.2007.11.037 18054825 1:CAS:528:DC%2BD1cXns1ejsbc%3D
- (2008) Eur Urol , vol.53 , pp. 917
- Bhojani¹

42
- 0036569472
- Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
- DOI 10.1200/JCO.2002.11.123
- Motzer 2002 J Clin Oncol 20 2376 10.1200/JCO.2002.11.123 11981011 (Pubitemid 34441667)
- (2002) Journal of Clinical Oncology , vol.20 , Issue.9 , pp. 2376-2381
- Motzer, R.J.¹ Bacik, J.² Mariani, T.³ Russo, P.⁴ Mazumdar, M.⁵ Reuter, V.⁶

43
- 71049154727
- A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC)
- abstr 5103
- Srinivasan R, Linehan WM, Vaishampayan U et al (2009) A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 27:(suppl; abstr 5103)
- (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
- Srinivasan, R.¹ Linehan, W.M.² Vaishampayan, U.³

44
- 58249094490
- 10.1200/JCO.2008.18.0000 19064974
- Golshayan 2009 J Clin Oncol 27 235 10.1200/JCO.2008.18.0000 19064974
- (2009) J Clin Oncol , vol.27 , pp. 235
- Golshayan¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.